Monday, November 02, 2015

eyeforpharma December Forum: Registration Deadline This Week

eyeforpharma Real World Evidence & Market Access Summit 2015
December 3-4, 2015 | Philadelphia, PA
www.eyeforpharma.com/rwe/


You know it and have read it here before: pharma leaders in data, HEOR, and market access need to come together to collaborate with health systems and physician leaders.

The 4th annual Real World Evidence & Market Access Summit on December 3-4 will be big pharma’s last opportunity to shape the evidence strategy for 2016 – and the only one with all stakeholders present.

Here’s why the event is a must-attend:
  1. Payer/provider panel discussions: Talk risk-based contracting and discover directly how access and formulary decisions are evolving from the customer point of view. Hear from Jerrold Penso, Chief Medical & Quality Officer, AMGA and Steve Chick, Vice President, Comprehensive Health Insights, Humana
  2. 15+ major health systems: Explore new opportunities for data and evidence collaboration and meet directly with health systems. Engage with change-makers such as Eric Newman, Chief of Specialty Care Innovation & Integration, Geisinger
  3. 1 event, 5 tailor-made tracks: Choose from a menu of opportunities – plan each day around the insights that matter most to you (real world analytics, HEOR, market access, organizer customer groups and data partnerships)

HIGH-LEVEL DELEGATES

Attendees learn as much from the world-class speaking faculty as they learn from their peers. Recent registrants include:
  1. Clément François, Vice President, HEOR, US Lundbeck
  2. Faisal Mehmud, Vice President, Medical Affairs, Novartis Oncology
  3. John Hernandez, Global Vice President, HEOR, Abbott
  4. Garret Ingram, Vice President, Head of US Market Access, Sanofi
  5. David Tomala, Senior Director, Advanced Analytics, Express-Scripts
  6. Mark Weiner, Chief Medical Information Officer, Temple University Health System

We’ve already confirmed dozens senior participants from: Novartis / Otsuka/ Janssen Pharmaceuticals/ Hoffmann-La Roche/ UCB/ Bayer/ Novo Nordisk/ Daiichi Sankyo/ Genentech/ AbbVie/ Millennium / DSI/ Takeda/ Oracle / J&J/ Mount Sinai/ Geisinger/ Pfizer/ EMD Serono/ Shire / SAS/ Eisai…

For those who like to stay ahead of the curve in showing drug value, this is a must-attend.




The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

No comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...